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In general, Asian men and women had similar medication adherence rates as white men, except for a 17% lower use of beta-blockers in Asian women. These findings were noted despite similar rates of prescription usage at 30 days by race/ethnicity and gender 30-days post MI. The authors are to be commended for this effort, and in particular the thoughtful discussion of their findings. This manuscript is extremely important since only national, retrospective database information will capture background nationwide trends. Because the analyses incorporate 12 month medication usage prior to the index MI event, the analysis perhaps unintentionally takes into account pre-MI event medication factors that could affect post-MI adherence.
Nonetheless, some minor limitations of this manuscript are worthy of mention. First, as acknowledged by the authors, there is no information about aspirin use. Secondly, despite the "improvement' in accuracy of the Research Triangle Institute (RTI) methodology to identify race/ethnicity through first and last name recognition algorithms, obvious misclassification is possible and such an approach may be considered a form of stereotyping. Thirdly, since a third of subjects reside in the Southern United States (U.S), one wonders about reasons for the differential prevalence, an issue not addressed by this paper and perhaps might be outside of the except for a 17% lower use of beta-blockers in Asian women. These findings w we e ere e no no ote te ted d d de de desp spite imilar rates of prescription usage at 30 days by race/ethnicity and gender 30-days post MI. The au uth th hor or rs s s ar ar re e e to to to be e co co com mmended for this effort, and d d i i in n p particular the t t tho h ug ug ght ht htfu f l discussion of their fi fi ind d din i gs. This s m man an nus usc cr crip ip pt t is is is e ex xt xtre reme me mely ly y i im mpo o ort t tant si in nce e e o on only ly y n n nat ati io on na nal, l r r ret etro rosp sp spe ec ecti tive ve ve d d dat at tab ab ba as ase e n nfo fo form rm mat atio ion n n wi w will ll ca ap aptu tu ure e e b bac ackg kg kgro ro roun un und d d n na nati ti tion on onwi wi wide de d t t tre en end d ds. Be Be Beca ca aus us u e e e th th he e e an an na al alys yses es e i i inc nc cor or orpo por r rat te te 1 12 2 2 month medica ca ati ti tion on on u u usa sa sage ge ge p pri ri rior or or t to o o th th t e e e in n nde de dex x x MI MI MI e e eve ve v nt nt nt, , , th the e e an an anal al a ys ys ysis is is p p per er e ha ha haps ps ps u u uni nint nt nten en enti ti ion on onally takes current scope. Fourth, while this analysis lacks associated CVD outcome data, these results suggest that health policy efforts must cross the threshold of access to care based primarily on insurance to include implementation efforts aimed at social and psychological barriers to long term-care continuity. The influence of biological, social and structural factors on racial/ethnic and gender differences in adherence to evidence based medications must be addressed.
Unfortunately, a majority of published work related to insurance subsidies is yet to examine the glaring issue of extremely different lifestyles by gender along the spectrum of racial/ethnic groups in the U.S. For example, unique stressors experienced by elderly black women such as lack of comprehensive social support, demands to be the stabilizing elderly parent or caregiver of multiple family generations, lack of wealth or access to a comfortable "nesting location/situation" might significantly impact medication adherence. Additionally, recognition and acknowledgement that ethnic heterogeneity exists among blacks and Hispanics as in other racial/ethnic groups is crucial to strategies aimed at minimizing post-MI outcome disparities. Psychological stressors faced by elderly black/Hispanic women can be magnified and are uniquely different than those faced by other socio-demographic groups once the intersection between race/ethnicity, gender and age are taken into consideration. Indeed, ignoring the latter and principally working under the assumption that provision of improved access to medications and quality health care will result in "a rising tide will float all boats" phenomenon is foolhardy.
In this respect, the authors of this paper do a nice job in their discussion section pointing out the significance of factors such as social support and other environmental determinants of health post-MI that need to be addressed if the differences by race/ethnicity and gender in their data are to be attenuated.
The interplay between social and biological issues can disproportionately and negatively parent or caregiver of multiple family generations, lack of wealth or access to a c co comf mf m or or orta ta tabl bl ble e e "nesting location/situation" might significantly impact medication adherence. Additionally, e eco co ogn gn gnit it itio io ion n n a an nd ac ac ackn knowledgement that ethnic he e ete te t r ro ogeneity exists ts s amo mo ong ng ng blacks and Hispanics as i in n n other raci cial al al/e /eth thni ni n c gr gr grou ou oups ps ps i is s cr cr cruc uc u ia ial l to s str r rateg g gi ie es a ai aim me med d d at at a m m min n nim imiz iz izin n ng g po po post st-M -M MI I I ou outc tco om ome e e di disp sp spar ar arit it i ie ies. s. . P P Psy sych ch ho ol olog og gic ical al a s str re es e so so sors rs rs f f fac ac ced suggests that elderly black and Hispanic Americans might be more susceptible to cognitive decline and dementia due to a combination of biological and cultural factors including variations in genetics, normative aging perception by race/ethnicity, health literacy and acculturation 2 . In turn, the amalgamation of cognitive decline and its associated stigma result in reluctance by the elderly patient, caregiver or health care provider to acknowledge or address cognitive decline.
Direct effects of cognitive decline on medication adherence include financial strain and depression due to patient forgetfulness, detrimental sleep patterns, and significant loss of household income from competing caregiver demands, typically in a backdrop of limited ability to psychologically and physically access organized assistance.
Variance in the prevalence of side-effects of beta-blocker, ACEI/ARB and statin medications according to socio-demographic issues and genetics also likely contributes to differences in medication adherence. For example, blacks and particularly older black women experience more cough and angioedema from ACEI/ARBs [3] [4] . Similarly, although the differential side-effect profile for statins remains controversial, data about increased risk of diabetes with statin exposure in women 5 , cognitive impairment with statin use in a cohort of subjects from the stroke belt that oversampled for blacks 6 , and the potential higher allele frequency related to the DR11 antigen linked to statin myopathy in black patients 7 need further investigation. Indeed, such information may pattern patient and provider beliefs about medication benefit versus risk in a manner that affects adherence. Interestingly, an analysis of the impact of exposure of evidence based pharmacotherapy after acute MI in older Medicare beneficiares noted mortality benefit was most impressive for statins followed by ACEI/ARBs, household income from competing caregiver demands, typically in a bac a kdrop of of f l lim im mit it ited ed ed a a abi bi bili lity ty o psychologically and physically access organized assistance. clopidogrel and beta-blockers respectively 8 . Interestingly, in this paper, statin use was generally higher than ACEI/ARB use, whereas beta-blockers had the highest penetration possibly due to longer provider acquaintance with this drug class.
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Structural factors including accessibility of transportation, pharmacy location, neighborhood safety, perceived discrimination and institutional attributes of health care entities/provider centers that affect communication quality between elderly minority/female patients and their providers also affects medication adherence. In a study by Kripalani S et al, transportation, counseling about medications and pharmacy wait times were cited as major additional barriers besides cost in filling prescriptions 9 .
In conclusion, so how do we cross the threshold of non-adherence for post-MI Medicare ev vid id iden en ent t t fr from om om f fin ind di din ng ngs s in n n t thi h s s ma ma manu nu nusc s scri ript pt pt i i ind nd ndica ca ati ti t n n ng t tha a at in in init it itia ia ati ti tion on n o o of f f s se ec co on nda da ary ry ry p p pre re ev ve vent nt tio on n f f f herapy, albei eit t t st st s il il ll l l su su s b-b-b op op o ti ti tima ma m l l wa wa w s s s no no on-n-n di di d ff ff ffer er eren en enti ti t al al al b by y ra ra race ce ce/e /e /eth th thni n n ci ci ity ty ty o o or r r ge ge gend nd n er er er. . Ad Ad Addi di d tionally, the patient and family/community centered cardiovascular care models. Undeniably, it remains fairly obvious that despite major advancements in drug therapies and implementation of evidence-based post MI management strategies, mortality from MI remains highest in blacks and among women highlighting the need to delve deeper into unique attributes that define the lives of these demographics. 
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